Loading…
The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease
Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our...
Saved in:
Published in: | European journal of nuclear medicine and molecular imaging 2024-05, Vol.51 (6), p.1662-1674 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3 |
container_end_page | 1674 |
container_issue | 6 |
container_start_page | 1662 |
container_title | European journal of nuclear medicine and molecular imaging |
container_volume | 51 |
creator | Gérard, Thomas Colmant, Lise Malotaux, Vincent Salman, Yasmine Huyghe, Lara Quenon, Lisa Dricot, Laurence Ivanoiu, Adrian Lhommel, Renaud Hanseeuw, Bernard |
description | Purpose
[
18
F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).
Methods
[
18
F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (
Braak
≤
2
,
Braak
≤
4
, and
Braak
≤
6
) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.
Results
The EOT in the
Braak
≤
2
region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R
2
+ 0.08–0.09) with the best correlation observed for EOT in the
Braak
≤
4
region (
R
2
= 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.
Conclusions
Quantifying [
18
F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD. |
doi_str_mv | 10.1007/s00259-024-06603-2 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11043108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3045402733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</originalsourceid><addsrcrecordid>eNp9kktuFDEQhlsIRELgAiyQJTZsGsrup1coihJABMFiWCFkVburpx167MF2TwgrrsEdOBUnwcOE4bFgY5dcn_9yuf4su8_hMQdongQAUckcRJlDXUORixvZIa-5zBto5c193MBBdieECwDeilbezg6KVqSg4YfZt8VILKwxGpwYfYpkI3MDizi7dDheMWfZO96evX_1Mq9FCdsMe3O6YGF0l4GF6J1dkmcYgtMmyST-0sSRabe0JpoNsTX5wfkVWk2BxRFtWlLNiLZH37N5HfEDsQ1OMzG_VWDGsuPp80hmRf77l6-B9SYQBrqb3RpwCnTvej_K3p6dLk6e5-evn704OT7PdSnqmBMMGkRfNVxrrEFiJ6lDTqVoKyp1V3Yl77UcUFdNWVegG9Fg39TY6aKSYiiOsqc73fXcrajX6VM8TmrtzQr9lXJo1N8Za0a1dBvFOZQFhzYpPLpW8O7jTCGqlQmapgktuTkoIXklJS9aSOjDf9ALN3ub-lMFlFUJoimKRIkdpb0LwdOwfw0HtXWD2rlBJTeon25QIl168Gcf-yu_xp-AYgeElNrO8Xft_8j-AMpqxL4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3045402733</pqid></control><display><type>article</type><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><source>Springer Link</source><creator>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</creator><creatorcontrib>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</creatorcontrib><description>Purpose
[
18
F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).
Methods
[
18
F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (
Braak
≤
2
,
Braak
≤
4
, and
Braak
≤
6
) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.
Results
The EOT in the
Braak
≤
2
region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R
2
+ 0.08–0.09) with the best correlation observed for EOT in the
Braak
≤
4
region (
R
2
= 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.
Conclusions
Quantifying [
18
F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-024-06603-2</identifier><identifier>PMID: 38228971</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnostic imaging ; Alzheimer's disease ; Biological Transport ; Biomarkers ; Brain ; Brain - diagnostic imaging ; Brain - metabolism ; Cardiology ; Cerebrospinal fluid ; Cognition ; Cognition & reasoning ; Cognitive ability ; Correlation ; Diagnostic systems ; Disease ; Female ; Humans ; Imaging ; Isoquinolines ; Male ; Medicine ; Medicine & Public Health ; Memory ; Middle Aged ; Missing data ; Neurodegenerative diseases ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Pathology ; Positron-Emission Tomography ; Radiology ; Radiopharmaceuticals - pharmacokinetics ; Sensitivity analysis ; Signs and symptoms ; Standard scores ; Tau protein ; tau Proteins - metabolism ; Tauopathies - diagnostic imaging</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2024-05, Vol.51 (6), p.1662-1674</ispartof><rights>The Author(s) 2024. corrected publication 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024, corrected publication 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</cites><orcidid>0009-0009-3568-3474 ; 0000-0002-3102-6778 ; 0000-0003-0737-9220 ; 0000-0002-8613-2420 ; 0000-0003-0668-6122 ; 0000-0001-7997-3945 ; 0009-0006-6511-0819 ; 0000-0001-9139-2422 ; 0000-0002-8564-5136</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38228971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gérard, Thomas</creatorcontrib><creatorcontrib>Colmant, Lise</creatorcontrib><creatorcontrib>Malotaux, Vincent</creatorcontrib><creatorcontrib>Salman, Yasmine</creatorcontrib><creatorcontrib>Huyghe, Lara</creatorcontrib><creatorcontrib>Quenon, Lisa</creatorcontrib><creatorcontrib>Dricot, Laurence</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Lhommel, Renaud</creatorcontrib><creatorcontrib>Hanseeuw, Bernard</creatorcontrib><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
[
18
F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).
Methods
[
18
F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (
Braak
≤
2
,
Braak
≤
4
, and
Braak
≤
6
) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.
Results
The EOT in the
Braak
≤
2
region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R
2
+ 0.08–0.09) with the best correlation observed for EOT in the
Braak
≤
4
region (
R
2
= 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.
Conclusions
Quantifying [
18
F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer's disease</subject><subject>Biological Transport</subject><subject>Biomarkers</subject><subject>Brain</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - metabolism</subject><subject>Cardiology</subject><subject>Cerebrospinal fluid</subject><subject>Cognition</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>Correlation</subject><subject>Diagnostic systems</subject><subject>Disease</subject><subject>Female</subject><subject>Humans</subject><subject>Imaging</subject><subject>Isoquinolines</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Memory</subject><subject>Middle Aged</subject><subject>Missing data</subject><subject>Neurodegenerative diseases</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pathology</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Sensitivity analysis</subject><subject>Signs and symptoms</subject><subject>Standard scores</subject><subject>Tau protein</subject><subject>tau Proteins - metabolism</subject><subject>Tauopathies - diagnostic imaging</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kktuFDEQhlsIRELgAiyQJTZsGsrup1coihJABMFiWCFkVburpx167MF2TwgrrsEdOBUnwcOE4bFgY5dcn_9yuf4su8_hMQdongQAUckcRJlDXUORixvZIa-5zBto5c193MBBdieECwDeilbezg6KVqSg4YfZt8VILKwxGpwYfYpkI3MDizi7dDheMWfZO96evX_1Mq9FCdsMe3O6YGF0l4GF6J1dkmcYgtMmyST-0sSRabe0JpoNsTX5wfkVWk2BxRFtWlLNiLZH37N5HfEDsQ1OMzG_VWDGsuPp80hmRf77l6-B9SYQBrqb3RpwCnTvej_K3p6dLk6e5-evn704OT7PdSnqmBMMGkRfNVxrrEFiJ6lDTqVoKyp1V3Yl77UcUFdNWVegG9Fg39TY6aKSYiiOsqc73fXcrajX6VM8TmrtzQr9lXJo1N8Za0a1dBvFOZQFhzYpPLpW8O7jTCGqlQmapgktuTkoIXklJS9aSOjDf9ALN3ub-lMFlFUJoimKRIkdpb0LwdOwfw0HtXWD2rlBJTeon25QIl168Gcf-yu_xp-AYgeElNrO8Xft_8j-AMpqxL4</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Gérard, Thomas</creator><creator>Colmant, Lise</creator><creator>Malotaux, Vincent</creator><creator>Salman, Yasmine</creator><creator>Huyghe, Lara</creator><creator>Quenon, Lisa</creator><creator>Dricot, Laurence</creator><creator>Ivanoiu, Adrian</creator><creator>Lhommel, Renaud</creator><creator>Hanseeuw, Bernard</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0009-3568-3474</orcidid><orcidid>https://orcid.org/0000-0002-3102-6778</orcidid><orcidid>https://orcid.org/0000-0003-0737-9220</orcidid><orcidid>https://orcid.org/0000-0002-8613-2420</orcidid><orcidid>https://orcid.org/0000-0003-0668-6122</orcidid><orcidid>https://orcid.org/0000-0001-7997-3945</orcidid><orcidid>https://orcid.org/0009-0006-6511-0819</orcidid><orcidid>https://orcid.org/0000-0001-9139-2422</orcidid><orcidid>https://orcid.org/0000-0002-8564-5136</orcidid></search><sort><creationdate>20240501</creationdate><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><author>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer's disease</topic><topic>Biological Transport</topic><topic>Biomarkers</topic><topic>Brain</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - metabolism</topic><topic>Cardiology</topic><topic>Cerebrospinal fluid</topic><topic>Cognition</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>Correlation</topic><topic>Diagnostic systems</topic><topic>Disease</topic><topic>Female</topic><topic>Humans</topic><topic>Imaging</topic><topic>Isoquinolines</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Memory</topic><topic>Middle Aged</topic><topic>Missing data</topic><topic>Neurodegenerative diseases</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pathology</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Sensitivity analysis</topic><topic>Signs and symptoms</topic><topic>Standard scores</topic><topic>Tau protein</topic><topic>tau Proteins - metabolism</topic><topic>Tauopathies - diagnostic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gérard, Thomas</creatorcontrib><creatorcontrib>Colmant, Lise</creatorcontrib><creatorcontrib>Malotaux, Vincent</creatorcontrib><creatorcontrib>Salman, Yasmine</creatorcontrib><creatorcontrib>Huyghe, Lara</creatorcontrib><creatorcontrib>Quenon, Lisa</creatorcontrib><creatorcontrib>Dricot, Laurence</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Lhommel, Renaud</creatorcontrib><creatorcontrib>Hanseeuw, Bernard</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gérard, Thomas</au><au>Colmant, Lise</au><au>Malotaux, Vincent</au><au>Salman, Yasmine</au><au>Huyghe, Lara</au><au>Quenon, Lisa</au><au>Dricot, Laurence</au><au>Ivanoiu, Adrian</au><au>Lhommel, Renaud</au><au>Hanseeuw, Bernard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>51</volume><issue>6</issue><spage>1662</spage><epage>1674</epage><pages>1662-1674</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
[
18
F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).
Methods
[
18
F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (
Braak
≤
2
,
Braak
≤
4
, and
Braak
≤
6
) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.
Results
The EOT in the
Braak
≤
2
region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R
2
+ 0.08–0.09) with the best correlation observed for EOT in the
Braak
≤
4
region (
R
2
= 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.
Conclusions
Quantifying [
18
F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38228971</pmid><doi>10.1007/s00259-024-06603-2</doi><tpages>13</tpages><orcidid>https://orcid.org/0009-0009-3568-3474</orcidid><orcidid>https://orcid.org/0000-0002-3102-6778</orcidid><orcidid>https://orcid.org/0000-0003-0737-9220</orcidid><orcidid>https://orcid.org/0000-0002-8613-2420</orcidid><orcidid>https://orcid.org/0000-0003-0668-6122</orcidid><orcidid>https://orcid.org/0000-0001-7997-3945</orcidid><orcidid>https://orcid.org/0009-0006-6511-0819</orcidid><orcidid>https://orcid.org/0000-0001-9139-2422</orcidid><orcidid>https://orcid.org/0000-0002-8564-5136</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1619-7070 |
ispartof | European journal of nuclear medicine and molecular imaging, 2024-05, Vol.51 (6), p.1662-1674 |
issn | 1619-7070 1619-7089 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11043108 |
source | Springer Link |
subjects | Aged Aged, 80 and over Alzheimer Disease - diagnostic imaging Alzheimer's disease Biological Transport Biomarkers Brain Brain - diagnostic imaging Brain - metabolism Cardiology Cerebrospinal fluid Cognition Cognition & reasoning Cognitive ability Correlation Diagnostic systems Disease Female Humans Imaging Isoquinolines Male Medicine Medicine & Public Health Memory Middle Aged Missing data Neurodegenerative diseases Nuclear Medicine Oncology Original Original Article Orthopedics Pathology Positron-Emission Tomography Radiology Radiopharmaceuticals - pharmacokinetics Sensitivity analysis Signs and symptoms Standard scores Tau protein tau Proteins - metabolism Tauopathies - diagnostic imaging |
title | The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A23%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20spatial%20extent%20of%20tauopathy%20on%20%5B18F%5DMK-6240%20tau%20PET%20shows%20stronger%20association%20with%20cognitive%20performances%20than%20the%20standard%20uptake%20value%20ratio%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=G%C3%A9rard,%20Thomas&rft.date=2024-05-01&rft.volume=51&rft.issue=6&rft.spage=1662&rft.epage=1674&rft.pages=1662-1674&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-024-06603-2&rft_dat=%3Cproquest_pubme%3E3045402733%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3045402733&rft_id=info:pmid/38228971&rfr_iscdi=true |